The BioCryst Pharmaceuticals Inc. (BCRX) Receives Consensus Rating of “Hold” from Brokerages

Posted under Uncategorized on December 10th, 2016 by

The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.04. The firm earned $4.80 million …

Leave a Comment